α-Difluoromethylornithine as treatment for metastatic breast cancer patients

Joyce A. O'Shaughnessy, Laurence M. Demers, Stephen E. Jones, James Arseneau, Pankaj Khandelwal, Timothy George, Robert Gersh, David Mauger, Andrea Manni

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

DFMO (α-difluoromethylornithine) is an oral irreversible inhibitor of ornithine decarboxylase, the first rate-limiting enzyme in polyamine synthesis. DFMO has been shown to have antiproliferative effects against several human cancers, and some studies have suggested that DFMO may have pro-apoptotic and anti-invasive properties as well. DFMO is well tolerated with minimal toxicity but has been associated with ototoxicity with prolonged daily administration. We conducted a Phase I/II tolerability, pharmacokinetic, and efficacy study of high-dose DFMO in metastatic breast cancer patients. Twenty-one patients were treated with 4800 mg of DFMO p.o. three times a day for 14 days, followed by a 2-week drug holiday on a 28-day cycle. Urinary polyamine and blood DFMO levels were measured at multiple time points during therapy. High-dose DFMO was well tolerated, and no clinically significant ototoxicity was noted. No patient achieved an objective antitumor response; however, one patient with heavily pretreated liver metastases has achieved stable disease for 18 months to date on DFMO. Putrescine, spermine, and spermidine urinary levels were suppressed with DFMO treatment and remained low during the 2-week drug holiday. High-dose DFMO on a schedule of 2 weeks on treatment followed by 2 weeks off is well tolerated, is not associated with ototoxicity, and leads to sustained suppression of urinary polyamine levels. Although not an active cytotoxic agent for metastatic breast cancer, the intriguing prolonged growth arrest of liver metastases in one patient highlights the potential clinical growth inhibitory properties of DFMO. We believe that DFMO is worthy of study as adjuvant therapy in primary breast cancer patients and as a chemopreventive agent.

Original languageEnglish (US)
Pages (from-to)3438-3444
Number of pages7
JournalClinical Cancer Research
Volume5
Issue number11
StatePublished - Nov 1 1999

Fingerprint

Eflornithine
Breast Neoplasms
Therapeutics
Polyamines
Holidays
Neoplasm Metastasis
Putrescine
Spermidine
Spermine
Liver
Cytotoxins
Growth
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

O'Shaughnessy, J. A., Demers, L. M., Jones, S. E., Arseneau, J., Khandelwal, P., George, T., ... Manni, A. (1999). α-Difluoromethylornithine as treatment for metastatic breast cancer patients. Clinical Cancer Research, 5(11), 3438-3444.
O'Shaughnessy, Joyce A. ; Demers, Laurence M. ; Jones, Stephen E. ; Arseneau, James ; Khandelwal, Pankaj ; George, Timothy ; Gersh, Robert ; Mauger, David ; Manni, Andrea. / α-Difluoromethylornithine as treatment for metastatic breast cancer patients. In: Clinical Cancer Research. 1999 ; Vol. 5, No. 11. pp. 3438-3444.
@article{b6b5f010117e42e186dce648d5ec304e,
title = "α-Difluoromethylornithine as treatment for metastatic breast cancer patients",
abstract = "DFMO (α-difluoromethylornithine) is an oral irreversible inhibitor of ornithine decarboxylase, the first rate-limiting enzyme in polyamine synthesis. DFMO has been shown to have antiproliferative effects against several human cancers, and some studies have suggested that DFMO may have pro-apoptotic and anti-invasive properties as well. DFMO is well tolerated with minimal toxicity but has been associated with ototoxicity with prolonged daily administration. We conducted a Phase I/II tolerability, pharmacokinetic, and efficacy study of high-dose DFMO in metastatic breast cancer patients. Twenty-one patients were treated with 4800 mg of DFMO p.o. three times a day for 14 days, followed by a 2-week drug holiday on a 28-day cycle. Urinary polyamine and blood DFMO levels were measured at multiple time points during therapy. High-dose DFMO was well tolerated, and no clinically significant ototoxicity was noted. No patient achieved an objective antitumor response; however, one patient with heavily pretreated liver metastases has achieved stable disease for 18 months to date on DFMO. Putrescine, spermine, and spermidine urinary levels were suppressed with DFMO treatment and remained low during the 2-week drug holiday. High-dose DFMO on a schedule of 2 weeks on treatment followed by 2 weeks off is well tolerated, is not associated with ototoxicity, and leads to sustained suppression of urinary polyamine levels. Although not an active cytotoxic agent for metastatic breast cancer, the intriguing prolonged growth arrest of liver metastases in one patient highlights the potential clinical growth inhibitory properties of DFMO. We believe that DFMO is worthy of study as adjuvant therapy in primary breast cancer patients and as a chemopreventive agent.",
author = "O'Shaughnessy, {Joyce A.} and Demers, {Laurence M.} and Jones, {Stephen E.} and James Arseneau and Pankaj Khandelwal and Timothy George and Robert Gersh and David Mauger and Andrea Manni",
year = "1999",
month = "11",
day = "1",
language = "English (US)",
volume = "5",
pages = "3438--3444",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

O'Shaughnessy, JA, Demers, LM, Jones, SE, Arseneau, J, Khandelwal, P, George, T, Gersh, R, Mauger, D & Manni, A 1999, 'α-Difluoromethylornithine as treatment for metastatic breast cancer patients', Clinical Cancer Research, vol. 5, no. 11, pp. 3438-3444.

α-Difluoromethylornithine as treatment for metastatic breast cancer patients. / O'Shaughnessy, Joyce A.; Demers, Laurence M.; Jones, Stephen E.; Arseneau, James; Khandelwal, Pankaj; George, Timothy; Gersh, Robert; Mauger, David; Manni, Andrea.

In: Clinical Cancer Research, Vol. 5, No. 11, 01.11.1999, p. 3438-3444.

Research output: Contribution to journalArticle

TY - JOUR

T1 - α-Difluoromethylornithine as treatment for metastatic breast cancer patients

AU - O'Shaughnessy, Joyce A.

AU - Demers, Laurence M.

AU - Jones, Stephen E.

AU - Arseneau, James

AU - Khandelwal, Pankaj

AU - George, Timothy

AU - Gersh, Robert

AU - Mauger, David

AU - Manni, Andrea

PY - 1999/11/1

Y1 - 1999/11/1

N2 - DFMO (α-difluoromethylornithine) is an oral irreversible inhibitor of ornithine decarboxylase, the first rate-limiting enzyme in polyamine synthesis. DFMO has been shown to have antiproliferative effects against several human cancers, and some studies have suggested that DFMO may have pro-apoptotic and anti-invasive properties as well. DFMO is well tolerated with minimal toxicity but has been associated with ototoxicity with prolonged daily administration. We conducted a Phase I/II tolerability, pharmacokinetic, and efficacy study of high-dose DFMO in metastatic breast cancer patients. Twenty-one patients were treated with 4800 mg of DFMO p.o. three times a day for 14 days, followed by a 2-week drug holiday on a 28-day cycle. Urinary polyamine and blood DFMO levels were measured at multiple time points during therapy. High-dose DFMO was well tolerated, and no clinically significant ototoxicity was noted. No patient achieved an objective antitumor response; however, one patient with heavily pretreated liver metastases has achieved stable disease for 18 months to date on DFMO. Putrescine, spermine, and spermidine urinary levels were suppressed with DFMO treatment and remained low during the 2-week drug holiday. High-dose DFMO on a schedule of 2 weeks on treatment followed by 2 weeks off is well tolerated, is not associated with ototoxicity, and leads to sustained suppression of urinary polyamine levels. Although not an active cytotoxic agent for metastatic breast cancer, the intriguing prolonged growth arrest of liver metastases in one patient highlights the potential clinical growth inhibitory properties of DFMO. We believe that DFMO is worthy of study as adjuvant therapy in primary breast cancer patients and as a chemopreventive agent.

AB - DFMO (α-difluoromethylornithine) is an oral irreversible inhibitor of ornithine decarboxylase, the first rate-limiting enzyme in polyamine synthesis. DFMO has been shown to have antiproliferative effects against several human cancers, and some studies have suggested that DFMO may have pro-apoptotic and anti-invasive properties as well. DFMO is well tolerated with minimal toxicity but has been associated with ototoxicity with prolonged daily administration. We conducted a Phase I/II tolerability, pharmacokinetic, and efficacy study of high-dose DFMO in metastatic breast cancer patients. Twenty-one patients were treated with 4800 mg of DFMO p.o. three times a day for 14 days, followed by a 2-week drug holiday on a 28-day cycle. Urinary polyamine and blood DFMO levels were measured at multiple time points during therapy. High-dose DFMO was well tolerated, and no clinically significant ototoxicity was noted. No patient achieved an objective antitumor response; however, one patient with heavily pretreated liver metastases has achieved stable disease for 18 months to date on DFMO. Putrescine, spermine, and spermidine urinary levels were suppressed with DFMO treatment and remained low during the 2-week drug holiday. High-dose DFMO on a schedule of 2 weeks on treatment followed by 2 weeks off is well tolerated, is not associated with ototoxicity, and leads to sustained suppression of urinary polyamine levels. Although not an active cytotoxic agent for metastatic breast cancer, the intriguing prolonged growth arrest of liver metastases in one patient highlights the potential clinical growth inhibitory properties of DFMO. We believe that DFMO is worthy of study as adjuvant therapy in primary breast cancer patients and as a chemopreventive agent.

UR - http://www.scopus.com/inward/record.url?scp=0032713928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032713928&partnerID=8YFLogxK

M3 - Article

C2 - 10589756

AN - SCOPUS:0032713928

VL - 5

SP - 3438

EP - 3444

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 11

ER -

O'Shaughnessy JA, Demers LM, Jones SE, Arseneau J, Khandelwal P, George T et al. α-Difluoromethylornithine as treatment for metastatic breast cancer patients. Clinical Cancer Research. 1999 Nov 1;5(11):3438-3444.